Puma Biotechnology Inc
PBYI
Positions held
Your positionsPBYI isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $514.65M | Enterprise value | $425.57M | Trailing P/E | 19.55 | Forward P/E | 28.49 |
| PEG | — | Price / book | 3.68 | Beta | 1.21 | Dividend yield | 0.00% |
| Revenue growth | 7.8% | Earnings growth | 35.8% | Gross margin | 74.8% | Operating margin | 13.4% |
| Profit margin | 11.6% | ROE | 22.0% | ROA | 9.8% | Debt / equity | 0.03 |
| Current ratio | 2.91 | Free cash flow | $32.47M | Analyst recommendation | none | Mean target | — |
| 52w high | $10.10 | 52w low | $4.58 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $56.5M | $44.8M | $75.5M | $54.5M | $52.4M |
| Op margin | 13.4% | -8.5% | 22.7% | 17.6% | 12.7% |
| Net income | $8.2M | -$3.8M | $13.4M | $8.8M | $5.9M |
| Gross margin | 77.9% | 76.7% | 69.3% | 77.7% | 76.5% |
| Gross profit | $44.0M | $34.4M | $52.3M | $42.3M | $40.1M |
| Operating income | $7.6M | -$3.8M | $17.1M | $9.6M | $6.6M |
- Revenue +26% vs prior quarter ($57M vs $45M).
- Gross margin 77.9% (was 76.7% prior quarter).
- Operating margin expanded to 13.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $228M | $230M | $236M | $228M | — |
| Op margin | 16.3% | 13.4% | 13.9% | 13.5% | — |
| Net income | $31.1M | $30.3M | $21.6M | $0.0M | — |
| Gross margin | 74.5% | 72.1% | 73.4% | 75.8% | — |
| Gross profit | $170M | $166M | $173M | $173M | — |
| Operating income | $37.3M | $31.0M | $32.6M | $30.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2026-09-18 · PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
2026-09-09 · Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
2026-09-09 · Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?
2026-09-03 · Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-08-14 · Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript
2026-08-12 · Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
2026-08-07 · PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
2026-08-07 · Puma Biotechnology, Inc. Q2 2026 Earnings Call Summary
2026-08-07 · Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ...
2026-08-06 · Puma Biotech: Q2 Earnings Snapshot
Price (daily)
Full chart · RSI · MACD · patterns